3 Takeaways from Puma Biotechnology's 2018 Earnings

Despite wielding a drug with blockbuster potential, Puma Biotechnology (NASDAQ: PBYI) was powerless to stop its shares from losing nearly 80% in value last year. Wall Street analysts worried about the slow pace of sales growth for Nerlynx, the company's only drug asset, but those concerns may be subsiding after the company had a strong showing for the fourth quarter.